Vaccinogen Announces that Swissmedic Health Authorities Granted Its Swiss Distribution Partner, ProVaccine, Permission to Export Biopsies and Import Vaccines on behalf of Vaccinogen.
- October 22, 2009
- Vaccinogen Announces New Relationship with CRO Clinipace Worldwide
- July 24, 2009
- Vaccinogen Announces Submission of Final Documentation to Swissmedic for Pivotal Review of OncoVAX®
- April 20, 2009
- Vaccinogen Announces That Michael G. Hanna, Jr., Ph.D. is Scheduled to Speak at the Barcelona Vaccine Forum 2009 in June 2009
- February 11, 2008
- Cancer Pioneer Reaches Key Agreement On Colon Cancer Drug OncoVAX®
- November 3, 2007
- Vaccinogen Announces Completion of its Initial Capitalization Plan
- October 1, 2007
- Vaccinogen Announces Formation of Company
- July 19, 2006
- FDA Grants Special Protocol Assessment
Frederick, MD USA/Baar, Switzerland – November 14, 2008 - Vaccinogen is pleased to announce that ProVaccine, its Swiss-based distribution partner for OncoVAX®, has been granted permission to export biopsies and import vaccines for OncoVAX® in Switzerland.
“We are delighted but not surprised to receive this good news for both Vaccinogen and ProVaccine.” says Michael G. Hanna, Jr., Ph.D., Vaccinogen’s Chairman & CEO. “Our partners at ProVaccine enjoy an excellent relationship with Swissmedic as a result of their commitment to excellence.”
Vaccinogen already has established in Neuchâtel, Switzerland, a preparation laboratory for the final preparation of the vaccines and doctor’s can apply the vaccine under patient named use to Swiss and foreign patients on a self-pay basis. The decision by Swiss Medic to permit ProVaccine to import OncoVAX® enables ProVaccine to represent OncoVAX® under its own name. The process leading up to this decision started in December 2007 and involved a thorough inspection of the ProVaccine staff, policies, procedures and command of OncoVAX®.
Establishing ProVaccine as the importer for OncoVAX® is the final step towards
granting OncoVAX® full registration status, thus paving the way for Swiss insurance
reimbursement for Swiss patients and opportunities for certain other countries to adopt the Swiss registration for their respective countries. Final OncoVAX® registration decision by Swiss Medic is expected in 2009.
About OncoVAX®
OncoVAX® immunotherapy is based on a decades-long attempt by scientists to transform the body’s immune response and its long-term memory to prevent the return of disease years after surgery. Such an approach has already been successful in preventing a number of infectious diseases.
About Vaccinogen
Vaccinogen is a biopharmaceutical company that develops and commercializes cancer vaccines and other immunotherapeutic products – Turning Cancer on Itself™. Based in Frederick, MD, the company has a portfolio of product candidates for the treatment of cancer, infectious disease, autoimmune, anti-inflammatory diseases and fully human monoclonal antibodies in various stages of clinical development.
www.vaccinogeninc.com
Vaccinogen’s online press kit: http://www.vaccinogeninc.com/
Contact:
Andrew L. Tussing
Vaccinogen
atussing@vaccinogeninc.com
301-668-8400